Publication
Characterization of CYP2C19*17 polymorphism in a Portuguese population sample relevant for proton pump inhibitor therapy : a pilot study
| dc.contributor.author | Ferraz, Adriana M. L. | |
| dc.contributor.author | Bandarra, Susana | |
| dc.contributor.author | Mascarenhas, Paulo | |
| dc.contributor.author | Barahona, Isabel | |
| dc.contributor.author | Martins, Rui | |
| dc.contributor.author | Ribeiro, Ana Clara | |
| dc.date.accessioned | 2022-05-18T11:49:15Z | |
| dc.date.available | 2022-05-18T11:49:15Z | |
| dc.date.issued | 2021 | |
| dc.description | Communication abstract: Proceedings of the 5th International Congress of CiiEM - Reducing inequalities in Health and Society, held at Egas Moniz’ University Campus in Monte de Caparica, Almada, from June 16th to 18th, 2021. | pt_PT |
| dc.description | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | pt_PT |
| dc.description.abstract | The interindividual variability of Proton Pump Inhibitor (PPI) therapy results from the phenotype variability associated with the cytochrome P450 2C19 (CYP2C19) gene, namely the CYP2C19*17 allele. Our aim was to characterize patients’ genetic variability undergoing PPI therapy. A sample of 33 oral mucosa cells from Portuguese pharmacy patients was collected, followed by genotyping. The allelic frequencies of CYP2C19*1 (-806C) and CYP2C19*17 (-806T) were 71.2% and 28.8%, respectively. The genotypic frequencies for CYP2C19*1/*1 and CYP2C19*1/*17 were 42.4% and 57.6%, respectively, and 19 of these patients may have a Rapid Metabolizer (RM) phenotype pharmaceutical opinion letter, based on genetic evidence. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Ferraz AML, Bandarra S, Mascarenhas P, Barahona I, Martins R, Ribeiro AC. Characterization of CYP2C19*17 Polymorphism in a Portuguese Population Sample Relevant for Proton Pump Inhibitor Therapy—A Pilot Study. Medical Sciences Forum. 2021; 5(1):19. https://doi.org/10.3390/msf2021005019 | pt_PT |
| dc.identifier.doi | 10.3390/msf2021005019 | pt_PT |
| dc.identifier.isbn | 978-3-0365-2238-8 | |
| dc.identifier.isbn | 978-3-0365-2237-1 | |
| dc.identifier.issn | 2673-9992 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/40610 | |
| dc.language.iso | eng | pt_PT |
| dc.publisher | MDPI | pt_PT |
| dc.relation.publisherversion | https://doi.org/10.3390/msf2021005019 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Cytochrome P450 2C19 | pt_PT |
| dc.subject | Pharmacogenetics | pt_PT |
| dc.subject | Proton pump inhibitors | pt_PT |
| dc.title | Characterization of CYP2C19*17 polymorphism in a Portuguese population sample relevant for proton pump inhibitor therapy : a pilot study | pt_PT |
| dc.type | other | |
| dspace.entity.type | Publication | |
| oaire.citation.startPage | 19 | pt_PT |
| oaire.citation.title | Medical Sciences Forum | pt_PT |
| oaire.citation.volume | 5(1) | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | other | pt_PT |
Files
Original bundle
1 - 1 of 1